Pablo Bascuñana

Dr. Pablo Bascuñana


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2016 in Glia
Verified
Journal Article
Closed access
PDF file
EHEdwin Hernandez‐Garzón
Edwin Hernandez‐Garzón
AFAna M. Fernandez
Ana M. Fernandez
APAlberto Perez‐Alvarez
Alberto Perez‐Alvarez
LGLaura Genis
Laura Genis
PBPablo Bascuñana
Pablo Bascuñana
Ignacio Torres AlemanIgnacio Torres Aleman
Ignacio Torres Aleman

21 December 2016 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
GBGuy Bar‐Klein
Guy Bar‐Klein
RKRebecca Klee
Rebecca Klee
CBClaudia Brandt
Claudia Brandt
MBMarion Bankstahl
Marion Bankstahl
PBPablo Bascuñana
Pablo Bascuñana
Wolfgang LöscherWolfgang Löscher
Wolfgang Löscher

8 May 2018 in eneuro
Verified
Journal Article
Open access
PDF file
MBMarion Bankstahl
Marion Bankstahl
HBHeike Breuer
Heike Breuer
ILIna Leiter
Ina Leiter
MMMartin Märkel
Martin Märkel
PBPablo Bascuñana
Pablo Bascuñana
WHWolfgang Härtig
Wolfgang Härtig
Increased permeability of the blood–brain barrier (BBB) following cerebral injury results in regional extravasation of plasma proteins and can critically contribute to the pathogenesis of epilepsy. Here, we comprehensively explore the spatiotemporal evolution of a main extravasation component, albumin, and illuminate associated responses of the neurovascular unit (NVU) contributing to early epileptogenic neuropathology. We applied translationalin vivoMR imaging and complementary immunohistochemical analyses in the widely used rat pilocarpine post–status epilepticus (SE) model. The observed rapid BBB leakage affected major epileptogenesis-associated brain regions, peaked between 1 and 2 d post-SE, and rapidly declined thereafter, accompanied by cerebral edema generally following the same time course. At peak of BBB leakage, serum albumin colocalized with NVU constituents, such as vascular components, neurons, and brain immune cells. Surprisingly, astroglial markers did not colocalize with albumin, and aquaporin-4 (AQP4) was clearly reduced in areas of leaky BBB, indicating a severe disturbance of astrocyte-mediated endothelial-neuronal coupling. In addition, a distinct adaptive reorganization process of the NVU vasculature apparently takes place at sites of albumin presence, substantiated by reduced immunoreactivity of endothelial and changes in vascular basement membrane markers. Taken together, degenerative events at the level of the NVU, affecting vessels, astrocytes, and neurons, seem to outweigh reconstructive processes. Considering the rapidly occurring BBB leakage and subsequent impairment of the NVU, our data support the necessity of a prompt BBB-restoring treatment as one component of rational therapeutic intervention to prevent epileptogenesis and the development of other detrimental sequelae of SE.

22 July 2020 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
PBPablo Bascuñana
Pablo Bascuñana
LMLuisa Möhle
Luisa Möhle
MBMirjam Brackhan
Mirjam Brackhan
Jens PahnkeJens Pahnke
Jens Pahnke
Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases. Fingolimod is an agonist of sphingosine-1-phosphate (S1P) receptors. Its main pharmacologic effect is immunomodulation by lymphocyte homing, thereby reducing the numbers of T and B cells in circulation. Because of the ubiquitous expression of S1P receptors, other effects have also been described. Here, we review preclinical experiments evaluating the effects of treatment with fingolimod in neurodegenerative diseases other than MS, such as Alzheimer’s disease or epilepsy. Fingolimod has shown neuroprotective effects in different animal models of neurodegenerative diseases, summarized here, correlating with increased brain-derived neurotrophic factor and improved disease phenotype (cognition and/or motor abilities). As expected, treatment also induced reductions in different neuroinflammatory markers because of not only inhibition of lymphocytes but also direct effects on astrocytes and microglia. Furthermore, fingolimod treatment exhibited additional effects for specific neurodegenerative disorders, such as reduction of amyloid-β production, and antiepileptogenic properties. The neuroprotective effects exerted by fingolimod in these preclinical studies are reviewed and support the translation of fingolimod into clinical trials as treatment in neurodegenerative diseases beyond neuroinflammatory conditions (MS).

1 February 2020 in Neurobiology of Disease
Verified
Journal Article
Open access
ASAlina Schidlitzki
Alina Schidlitzki
PBPablo Bascuñana
Pablo Bascuñana
PSPrashant K. Srivastava
Prashant K. Srivastava
LWLisa Welzel
Lisa Welzel
FTFriederike Twele
Friederike Twele
Wolfgang LöscherWolfgang Löscher
Wolfgang Löscher
Epilepsy is a complex network phenomenon that, as yet, cannot be prevented or cured. We recently proposed network-based approaches to prevent epileptogenesis. For proof of concept we combined two drugs (levetiracetam and topiramate) for which in silico analysis of drug-protein interaction networks indicated a synergistic effect on a large functional network of epilepsy-relevant proteins. Using the intrahippocampal kainate mouse model of temporal lobe epilepsy, the drug combination was administered during the latent period before onset of spontaneous recurrent seizures (SRS). When SRS were periodically recorded by video-EEG monitoring after termination of treatment, a significant decrease in incidence and frequency of SRS was determined, indicating antiepileptogenic efficacy. Such efficacy was not observed following single drug treatment. Furthermore, a combination of levetiracetam and phenobarbital, for which in silico analysis of drug-protein interaction networks did not indicate any significant drug-drug interaction, was not effective to modify development of epilepsy. Surprisingly, the promising antiepileptogenic effect of the levetiracetam/topiramate combination was obtained in the absence of any significant neuroprotective or anti-inflammatory effects as indicated by multimodal brain imaging and histopathology. High throughput RNA-sequencing (RNA-seq) of the ipsilateral hippocampus of mice treated with the levetiracetam/topiramate combination showed that several genes that have been linked previously to epileptogenesis, were significantly differentially expressed, providing interesting entry points for future mechanistic studies. Overall, we have discovered a novel combination treatment with promise for prevention of epilepsy.

5 December 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
PBPablo Bascuñana
Pablo Bascuñana
AHAnnika Hess
Annika Hess
TBTobias Borchert
Tobias Borchert
YWYong Wang
Yong Wang
KWKai C. Wollert
Kai C. Wollert
JTJames T. Thackeray
James T. Thackeray
Acute myocardial infarction (MI) triggers a local and systemic inflammatory response. We recently showed microglia involvement using translocator protein imaging. Here, we evaluated whether 11C-methionine provides further insight into heart–brain inflammation networking. Methods: Male C57BL/6 mice underwent permanent coronary artery ligation followed by 11C-methionine PET at 3 and 7 d (n = 3). In subgroups, leukocyte homing was blocked by integrin antibodies (n = 5). The cellular substrate for PET signal was identified using brain section immunostaining. Results:11C-methionine uptake (percentage injected dose/cm3) peaked in the MI region on day 3 (5.9 ± 0.9 vs. 2.4 ± 0.5), decreasing to the control level by day 7 (4.3 ± 0.6). Brain uptake was proportional to cardiac uptake (r = 0.47, P < 0.05), peaking also on day 3 (2.9 ± 0.4 vs. 2.4 ± 0.3) and returning to baseline on day 7 (2.3 ± 0.4). Integrin blockade reduced uptake at every time point. Immunostaining on day 3 revealed colocalization of the l-type amino acid transporter, with glial fibrillary acidic protein–positive astrocytes but not CD68-positive microglia. Conclusion: PET imaging with 11C-methionine specifically identifies an astrocyte component, enabling further dissection of the heart–brain axis in post-MI inflammation.